Results: 1-25 | 26-37
Results: 1-25/37

Authors: Zellweger, T Miyake, H July, LV Akbari, M Kiyama, S Gleave, ME
Citation: T. Zellweger et al., Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin, NEOPLASIA, 3(4), 2001, pp. 360-367

Authors: Miyake, H Hara, S Zellweger, T Kamidono, S Gleave, ME Hara, I
Citation: H. Miyake et al., Acquisition of resistance to Fas-mediated apoptosis by overexpression of clusterin in human renal-cell carcinoma cells, MOL UROL, 5(3), 2001, pp. 105-111

Authors: Miyake, H Hara, I Kamidon, S Gleave, ME
Citation: H. Miyake et al., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting anti-apoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, INT J UROL, 8(7), 2001, pp. 337-349

Authors: Hara, I Miyake, H Gleave, ME Kamidono, S
Citation: I. Hara et al., Introduction of Clusterin gene into human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy through inhibition of apoptosis both in vitro and in vivo, JPN J CANC, 92(11), 2001, pp. 1220-1224

Authors: Trachtenberg, J Newling, DWW Gleave, ME Lubeck, DP Kirschenbaum, A Sylvester, J
Citation: J. Trachtenberg et al., Discussion following Dr. Geert J.C.M. Kolvenbag's presentation, UROLOGY, 58(2A), 2001, pp. 23-23

Authors: Daniell, HW Chen, S Fair, WR Heston, WDW Pirani, JF Bubley, GJ Carroll, PR Gleave, ME
Citation: Hw. Daniell et al., Discussion following Dr. Sophie Chen's (pages 28-35) and Dr. John F. Pirani's presentations, UROLOGY, 58(2A), 2001, pp. 38-38

Authors: Gleave, ME Miyake, H Zellweger, T Chi, K July, L Nelson, C Rennie, P
Citation: Me. Gleave et al., Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer, UROLOGY, 58(2A), 2001, pp. 39-48

Authors: Lieberman, R Gleave, ME Carroll, PR Bubley, GJ
Citation: R. Lieberman et al., Discussion following Dr. Martin E. Gleave's presentation, UROLOGY, 58(2A), 2001, pp. 48-49

Authors: Carroll, PR D'Amico, A Malkowicz, SB Gleave, ME Bubley, GJ
Citation: Pr. Carroll et al., Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 82-82

Authors: Fair, WR Newling, DWW Heston, WDW Trachtenberg, J Malkowicz, SB Gleave, ME
Citation: Wr. Fair et al., The role of diethylstilbestrol in the treatment of prostate cancer - Discussion, UROLOGY, 58(2A), 2001, pp. 113-113

Authors: Gleave, ME Goldenberg, SL Chin, JL Warner, J Saad, F Klotz, LH Jewett, M Kassabian, V Chetner, M Dupont, C Van Rensselaer, S
Citation: Me. Gleave et al., Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: Biochemical and pathological effects, J UROL, 166(2), 2001, pp. 500-506

Authors: Zellweger, T Miyake, H Cooper, S Chi, K Conklin, BS Monia, BP Gleave, ME
Citation: T. Zellweger et al., Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2 '-O-(2-methoxy)ethyl chemistry, J PHARM EXP, 298(3), 2001, pp. 934-940

Authors: Leung, S Miyake, H Zellweger, T Tolcher, A Gleave, ME
Citation: S. Leung et al., Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model, INT J CANC, 91(6), 2001, pp. 846-850

Authors: Gleave, ME Miyake, H Nelson, C Rennie, P Leung, S
Citation: Me. Gleave et al., Targeting antiapoptotic genes upregulated by androgen withdrawal using antisense oligodeoxynucleotides to enhance androgen-and chemo-sensitivity in prostate cancer, CONT CANC R, 2001, pp. 327-340

Authors: Miayake, H Tolcher, A Gleave, ME
Citation: H. Miayake et al., Chemosensitization and delayed androgen-independent recurrence of prostatecancer with the use of antisense Bcl-2 oligodeoxynucleotides, J NAT CANC, 92(1), 2000, pp. 34-41

Authors: Gleave, ME La Bianca, S Goldenberg, SL
Citation: Me. Gleave et al., Neoadjuvant hormonal therapy prior to radical prostatectomy: promises and pitfalls, PROSTATE C, 3(3), 2000, pp. 136-144

Authors: Bruchovsky, N Klotz, LH Sadar, M Crook, JM Hoffart, D Godwin, L Warkentin, M Gleave, ME Goldenberg, SL
Citation: N. Bruchovsky et al., Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations, MOL UROL, 4(3), 2000, pp. 191-199

Authors: Miyake, H Chi, KN Gleave, ME
Citation: H. Miyake et al., Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo, CLIN CANC R, 6(5), 2000, pp. 1655-1663

Authors: Ting, A Gleave, ME Hsiang, YN
Citation: A. Ting et al., Regarding "In situ replacement of the aorta in a contaminated field with the infrarenal inferior vena cava" - Reply, J VASC SURG, 31(3), 2000, pp. 625-626

Authors: Leung, SYL Jackson, J Miyake, H Burt, H Gleave, ME
Citation: Syl. Leung et al., Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors, PROSTATE, 44(2), 2000, pp. 156-163

Authors: Gleave, ME La Bianca, SE Goldenberg, SL Jones, EC Bruchovsky, N Sullivan, LD
Citation: Me. Gleave et al., Long-term neoadjuvant hormone therapy prior to radical prostatectomy: Evaluation of risk for biochemical recurrence at 5-year follow-up, UROLOGY, 56(2), 2000, pp. 289-294

Authors: Miyake, H Monia, BP Gleave, ME
Citation: H. Miyake et al., Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense bcl-xL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model, INT J CANC, 86(6), 2000, pp. 855-862

Authors: Miyake, H Nelson, C Rennie, PS Gleave, ME
Citation: H. Miyake et al., Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3 '-kinase pathway, ENDOCRINOL, 141(6), 2000, pp. 2257-2265

Authors: Miyake, H Nelson, C Rennie, PS Gleave, ME
Citation: H. Miyake et al., Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models, CANCER RES, 60(9), 2000, pp. 2547-2554

Authors: Sadar, MD Gleave, ME
Citation: Md. Sadar et Me. Gleave, Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells, CANCER RES, 60(20), 2000, pp. 5825-5831
Risultati: 1-25 | 26-37